Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Executives on a DealBook Summit task force panel said fear was not the way to build teams capable of navigating difficult ...

Chronic chikungunya arthritis often mimics rheumatoid arthritis, complicating diagnosis and therapy, and necessitating ...

The boss of Britain’s largest drug developer has praised the US as the best place to invest amid fears over the waning appeal ...

Harvey Jones asked artificial intelligence to prepare a portfolio of FTSE 100 stocks to yield him a passive income in ...

DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an ...

GlaxoSmithKline (GSK) announced the purchase of 250,000 of its own ordinary shares as part of its ongoing share buyback program. The shares were bought at prices ranging from 1,780.00p to 1,820.00p, ...

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, ...

The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE ...

FIDSON Healthcare Plc has reinforced its commitment to healthcare delivery, corporate governance, and strategic growth ...

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

Dame Emma Walmsley, Chief Executive one of Britain's biggest pharmaceutical companies GSK (GlaxoSmithKline), says the company is prioritising the United States for product launches and investment, ...